Reldesemtiv
- Generic Name
- Reldesemtiv
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C19H18F2N6O
- CAS Number
- 1345410-31-2
- Unique Ingredient Identifier
- 4S0HBYW6QE
- Background
Reldesemtiv is under investigation in clinical trial NCT03160898 (A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)).
- Associated Conditions
- -
- Associated Therapies
- -
A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)
- First Posted Date
- 2022-07-05
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 71
- Registration Number
- NCT05442775
- Locations
- ๐บ๐ธ
University of California Irvine - ALS & Neuromuscular Center, Orange, California, United States
๐บ๐ธMayo Clinic Jacksonville, Jacksonville, Florida, United States
๐บ๐ธMichigan Medicine, Ann Arbor, Michigan, United States
A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 489
- Registration Number
- NCT04944784
- Locations
- ๐บ๐ธ
Johns Hopkins Outpatient Center, Baltimore, Maryland, United States
๐ฆ๐บRoyal Brisbane and Women's Hospital, Herston, Queensland, Australia
๐บ๐ธCedars-Sinai Medical Center, Los Angeles, California, United States
A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS)
- First Posted Date
- 2017-05-19
- Last Posted Date
- 2020-09-11
- Lead Sponsor
- Cytokinetics
- Target Recruit Count
- 458
- Registration Number
- NCT03160898
- Locations
- ๐บ๐ธ
Washington University School of Medicine, Saint Louis, Missouri, United States
๐บ๐ธNeurology Associates, P.C., Lincoln, Nebraska, United States
๐บ๐ธWest Virginia University, Dept. of Neurology, Morgantown, West Virginia, United States
A Study to Assess the Anti-fatigability Effect of CK-2127107 in Elderly Male and Female Subjects With Limitations in Mobility
- First Posted Date
- 2017-02-28
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 42
- Registration Number
- NCT03065959
- Locations
- ๐บ๐ธ
Tufts Medical Center, Boston, Massachusetts, United States
๐บ๐ธWashington University School of Medicine, Saint Louis, Missouri, United States
๐บ๐ธOhio University Heritage College, Athens, Ohio, United States
A Study to Assess the Effect of CK-2127107 on Physical Function in Subjects With Chronic Obstructive Pulmonary Disease
- Conditions
- Interventions
- First Posted Date
- 2016-01-25
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT02662582
- Locations
- ๐บ๐ธ
Site US10001, Torrance, California, United States
๐บ๐ธSite US10003, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.